Radiation oncology firm Accuray has received approval from the Japanese Ministry of Health, Labor, and Welfare to market its CyberKnife M6 radiation therapy system.
CyberKnife M6 allows patients to lie comfortably and breathe freely while receiving high-dose radiation therapy in relatively few treatments, reducing side effects and preserving quality of life, according to Accuray.
In July 2010, Accuray was granted approval of the CyberKnife G4 system for use in Japan for the treatment of tumors in the body, including the head and neck. In 2012, the company received approval to market the CyberKnife VSI system for robotic radiosurgery.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
